Preview

Neurology, Neuropsychiatry, Psychosomatics

Advanced search

A patient with osteoarthritis out of a doctor's field of vision: how should joint pain be controlled within the concept of responsible self-treatment?

https://doi.org/10.14412/2074-2711-2019-2S-52-61

Full Text:

Abstract

The development of effective and safe treatments for osteoarthritis (OA), the most common chronic joint disease, is one of the main challenges facing modern medicine. Despite the fact that there are many drugs and non-drug therapies, the treatment of OA is not always successful, especially in terms of long-term prognosis. This is determined by the heterogeneity of OA, different phenotypes of this disease, as well as by a significant variability in its course, which complicates individual therapy choice. In this situation, a well-informed patient can become an effective physician assistant. Thus, the patient can control his/her condition in accordance with the responsible self-treatment principles: to assess therapy results and disease exacerbations, to maintain muscle tone and the necessary level of motor activity, to carry out therapeutic exercises, as well as to independently stop short-term increased pain episodes with over-the-counter analgesics. One of the most popular over-the-counter painkillers used worldwide is naproxen administered in low doses. This drug has proven to be an effective analgesic with good tolerability, standing out among all nonsteroidal anti-inflammatory drugs having a minimal risk for cardiovascular events. Teraliv 275 mg, a new over-thecounter formulation of naproxen, has currently emerged in Russia now. It seems that this medication will become an essential element of therapy for OA within the concept of responsible self-medication.

About the Author

A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
34A, Kashirskoye Shosse, Moscow 115522


References

1. Nasonov EL, editor. Russian clinical guidelines. Rheumatology. Moscow: GEOTAR-Media; 2017. 446 p. (In Russ.). ISBN 978-5-9704-4261-6

2. Murray CJ, Barber RM, Foreman KJ, et al. Global, regional, and national disabilityadjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Nov 28;386(10009):2145-91. doi: 10.1016/S0140-6736(15)61340-X. Epub 2015 Aug 28.

3. Xie F, Kovic B, Jin X, et al. Economic and Humanistic Burden of Osteoarthritis: A Systematic Review of Large Sample Studies. Pharmacoeconomics. 2016 Nov;34(11): 1087-100. doi: 10.1007/s40273-016-0424-x

4. Karateev AE, Lila AM. Osteoarthritis: current clinical concept and some promising therapeutic approaches. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018; 56(1):70-81 (In Russ.). doi: 10.14412/1995-4484-2018-70-81

5. Favero M, Ramonda R, Goldring MB, et al. Early knee osteoarthritis. RMD Open. 2015 Aug 15;1(Suppl 1):e000062. doi: 10.1136/rmdopen2015-000062. eCollection 2015.

6. Demographics. Official site of the Federal State Statistics Service [Electronic resource]. Available from: http://www.gks.ru/wps/wcm/connect/rosstat_main/rosstat/ru/statistics/population/demography/ (In Russ.).

7. Haugen IK, Ramachandran VS, Misra D, et al. Hand osteoarthritis in relation to mortality and incidence of cardiovascular disease. Ann Rheum Dis. 2015;74:74-81. doi: 10.1136/annrheumdis-2013-203789

8. Kluzek S, Sanchez-Santos MT, Leyland KM, et al. Painful knee but not hand osteoarthritis is an independent predictor of mortality over 23-years follow-up of a population-based cohort of middle-aged women. Ann Rheum Dis. 2016 Oct;75(10):1749-56. doi: 10.1136/annrheumdis-2015-208056. Epub 2015 Nov 5.

9. Veronese N, Cereda E, Maggi S, et al. Osteoarthritis and mortality: A prospective cohort study and systematic review with metaanalysis. Semin Arthritis Rheum. 2016 Oct;46(2): 160-7. doi: 10.1016/j.semarthrit.2016.04.002. Epub 2016 Apr 13.

10. Mendy A, Park J, Vieira ER. Osteoarthritis and risk of mortality in the USA: a population-based cohort study. Int J Epidemiol. 2018 Aug 29. doi: 10.1093/ije/dyy187 [Epub ahead of print].

11. Persson MSM, Sarmanova A, Doherty M, Zhang W. Conventional and biologic diseasemodifying anti-rheumatic drugs for osteoarthritis: a meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2018 Oct 1;57(10): 1830-7. doi: 10.1093/rheumatology/key131

12. Wang J. Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial. J Int Med Res. 2017 Jan 1:300060517723182. doi: 10.1177/ 0300060517723182

13. Meheux CJ, McCulloch PC, Lintner DM, et al. Efficacy of Intra-articular Platelet-Rich Plasma Injections in Knee Osteoarthritis: A Systematic Review. Arthroscopy. 2016 Mar;32(3): 495-505. doi: 10.1016/j.arthro.2015.08.005. Epub 2015 Oct 1.

14. Yazici Y, McAlindon TE, Fleischmann R, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthritis Cartilage. 2017 Oct;25(10): 1598-606. doi: 10.1016/j.joca.2017.07.006. Epub 2017 Jul 13.

15. Yang CY, Chanalaris A, Troeberg L. ADAMTS and ADAM metalloproteinases in osteoarthritis – looking beyond the 'usual suspects'. Osteoarthritis Cartilage. 2017 Jul;25(7): 1000-9. doi: 10.1016/j.joca.2017.02.791. Epub 2017 Feb 13.

16. Towheed T, Maxwell L, Anastassiades T, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD002946. doi: 10.1002/14651858. CD002946.pub2

17. Reichenbach S, Sterchi R, Scherer M, et al. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med. 2007;146(8): 580-90. doi: 10.7326/0003-4819-146-8-200704170-00009

18. Fidelix T, Soares B, Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005117. doi: 10.1002/14651858.CD005117.pub2

19. Clegg DO, Reda DJ, Harris CL, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med. 2006 Feb 23;354(8):795-808. doi: 10.1056/NEJMoa052771

20. Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010 Feb;69(2):374-9. doi: 10.1136/ard.2009.107805. Epub 2009 Apr 12.

21. Karateev AE, Pogozheva EYu, Amirdzhanova VN, Filatova ES. Hyaluronic acid preparations in the treatment of osteoarthritis: is it clear to us? Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2018;12(3):40-52 (In Russ.). doi: 10.14412/1996-7012-2018-3-40-52

22. Dell'Isola A, Steultjens M. Classification of patients with knee osteoarthritis in clinical phenotypes: Data from the osteoarthritis initiative. PLoS One. 2018 Jan 12;13(1):e0191045. doi: 10.1371/journal.pone.0191045. eCollection 2018.

23. Bastick AN, Wesseling J, Damen J, et al. Defining knee pain trajectories in early symptomatic knee osteoarthritis in primary care: 5-year results from a nationwide prospective cohort study (CHECK). Br J Gen Pract. 2016 Jan; 66(642):e32-9. doi: 10.3399/bjgp15X688129. Epub 2015 Dec 6.

24. Pan F, Tian J, Aitken D, et al. Predictors of pain severity trajectory in older adults: a 10.7-year follow-up study. Osteoarthritis Cartilage. 2018 Dec;26(12):1619-26. doi: 10.1016/j.joca.2018.08.002. Epub 2018 Aug 17.

25. Trouvin AP, Marty M, Goupille P, Perrot S. Determinants of daily pain trajectories and relationship with pain acceptability in hip and knee osteoarthritis. A national prospective cohort study on 886 patients. Joint Bone Spine. 2018 Jul 17. pii: S1297-319X(18)30137-4. doi: 10.1016/j.jbspin.2018.06.009 [Epub ahead of print].

26. Parry E, Ogollah R, Peat G. Significant pain variability in persons with, or at high risk of, knee osteoarthritis: preliminary investigation based on secondary analysis of cohort data. BMC Musculoskelet Disord. 2017 Feb 14;18(1): 80. doi: 10.1186/s12891-017-1434-3

27. Dominick KL, Golightly YM, Bosworth HB. Racial differences in analgesic/anti-inflammatory medication adherence among patients with osteoarthritis. Ethn Dis. 2005 Winter;15(1):116-22.

28. Margolis JM, Princic N, Smith DM, et al. Development of a novel algorithm to determine adherence to chronic pain treatment guidelines using administrative claims. J Pain Res. 2017 Feb 8;10:327-39. doi: 10.2147/JPR.S118248. eCollection 2017.

29. Kingsbury SR, Hensor EM, Walsh CA, et al. How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative. Arthritis Res Ther. 2013;15(5):R106. doi: 10.1186/ar4286

30. Gokhale M, Martin B. Prescription acquired acetaminophen use and potential overuse patterns: 2001-2008. Pharmacoepidemiol Drug Saf. 2012 Feb;21(2):226-30. doi:10.1002/pds.2235

31. Goodman SM, Mandl LA, Mehta B, et al. Does Education Level Mitigate the Effect of Poverty on Total Knee Arthroplasty Outcomes? Arthritis Care Res (Hoboken). 2017 Nov 22. doi: 10.1002/acr.23442

32. Geenen R, Overman CL, Christensen R, et al. EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018 Jun;77(6):797-807. doi: 10.1136/annrheumdis-2017-212662. Epub 2018 May 3.

33. Bruyere O, Cooper C, Pelletier JP, et al. A consensus statement on the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) algorithm for the management of knee osteoarthritis – From evidence-based medicine to the real-life setting. Semin Arthritis Rheum. 2016 Feb;45 (4 Suppl):S3-11. doi: 10.1016/j.semarthrit.2015. 11.010. Epub 2015 Dec 2.

34. Tolpygina SN, Martsevich SYu, Kontsevaya AV, Drapkina OM. Responsible self-care – the fundamental principles and place in the modern russian healthcare system. Ratsional'naya Farmakoterapiya v Kardiologii. 2018;14(1): 101-10 (In Russ.). doi: 10.20996/1819-6446-2018-14-1-101-110

35. Simental-Mendia M, Sanchez-Garcia A, Vilchez-Cavazos F, et al. Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and metaanalysis of randomized placebo-controlled trials. Rheumatol Int. 2018 Aug;38(8):1413-28. doi: 10.1007/s00296-018-4077-2. Epub 2018 Jun 11.

36. Bruyere O, Cooper C, Al-Daghri NM, et al. Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2018 Feb; 30(2):111-7. doi: 10.1007/s40520-017-0861-1. Epub 2017 Nov 24.

37. Zeng C, Wei J, Li H, et al. Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee. Sci Rep. 2015 Nov 18; 5:16827. doi: 10.1038/srep16827

38. Chichasova NV. Clinical rationale for the use of various teraflex formulations in osteoarthrosis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2010;4(4):59-64 (In Russ.). doi: 10.14412/1996-7012-2010-639

39. Alexeeva LI, Kashevarova NG, Sharapova EP, et al. Comparison of continuous and intermittent treatment of patients with knee osteoarthritis with combined drug “Teraflex”. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(3): 68-72 (In Russ.). doi: 10.14412/1995-4484-2008-662

40. Lila AM, Mazurov VI, Shidlovskaya OV, Shostak NA. Teraflex in the treatment of osteoarthritis of the knee and spinal osteochondrosis (the results of a clinical study). Russkii Meditsinskii Zhurnal. 2005;13(24):1618-22 (In Russ.).

41. Angiolillo DJ, Weisman SM. Clinical Pharmacology and Cardiovascular Safety of Naproxen. Am J Cardiovasc Drugs. 2017 Apr; 17(2):97-107. doi: 10.1007/s40256-016-0200-5

42. McGettigan P, Henry D. Use of nonsteroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle- and high-income countries. PLoS Med. 2013;10(2): e1001388. doi: 10.1371/journal.pmed.1001388

43. Aeidler H. Clinical results of a multicentral double-blind examination of naproxen compared to indomethacin in chronic rheumatoid arthritis, ankylosing spondylitis, and osteoarthrosis. Arzneimittelforschung. 1975;25(2A):315-8.

44. Bowers D, Dyer H, Fosdick W, et al. Naproxen in rheumatoid arthritis. A controlled trial. Ann Intern Med. 1975;83(4):470-5. doi: 10.7326/0003-4819-83-4-470

45. Clarke A. A double-blind comparison of naproxen against indometacin in osteoarthrosis. Arzneimittelforschung. 1975;25(2A):302-4.

46. Castles J, Moore T, Vaughan J, et al. Multicenter comparison of naproxen and indomethacin in rheumatoid arthritis. Arch Intern Med. 1978;138(3):362-6. doi: 10.1001/archinte.1978.03630270016011

47. Blechman W, Willkens R, Boncaldo G, et al. Naproxen in osteoarthrosis. Double-blind crossover trial. Ann Rheum Dis. 1978;37(1):80-4. doi: 10.1136/ard.37.1.80

48. Melton J 3rd, Lussier A, Ward J, et al. Naproxen vs. aspirin in osteoarthritis of the hip and knee. J Rheumatol. 1978;5(3):338-46.

49. Martinez-Lavin M, Holman K, Smyth C, Vaughan J. A comparison of naproxen, indomethacin and aspirin in osteoarthritis. J Rheumatol. 1980;7(5):711-6.

50. Bjö rkenheim J, Helland J, Peltonen J. A double-blind crossover evaluation of naproxen and piroxicam in osteoarthritis of hip or knee. J Int Med Res. 1985;13(5):263-9. doi: 10.1177/030006058501300503

51. Dunn T, Clark V, Jones G. Preoperative oral naproxen for pain relief after day-case laparoscopic sterilization. Br J Anaesth. 1995;75(1): 12-4. doi: 10.1093/bja/75.1.12

52. Comfort V, Code W, Rooney M, Yip R. Naproxen premedication reduces postoperative tubal ligation pain. Can J Anaesth. 1992;39(4): 349-52. doi: 10.1007/BF03009045

53. Code W, Yip R, Rooney M, et al. Preoperative naproxen sodium reduces postoperative pain following arthroscopic knee surgery. Can J Anaesth. 1994;41(2):98-101. doi: 10.1007/BF03009799

54. Malmstrom K, Kotey P, Coughlin H, Desjardins P. A randomized, double-blind, parallel-group study comparing the analgesic effect of etoricoxib to placebo, naproxen sodium, and acetaminophen with codeine using the dental impaction pain model. Clin J Pain. 2004;20(3): 147-55. doi: 10.1097/00002508-200405000-00004

55. Derry C, Derry S, Moore RA, McQuay HJ. Single dose oral naproxen and naproxen sodium for acute postoperative pain in adults. Cochrane Database Syst Rev. 2009 Jan 21;(1):CD004234. doi: 10.1002/14651858.CD004234.pub3

56. Mason L, Edwards JE, Moore RA, McQuay HJ. Single dose oral naproxen and naproxen sodium for acute postoperative pain. Cochrane Database Syst Rev. 2004 Oct 18;(4): CD004234. doi: 10.1002/14651858.CD004234. pub2

57. Sammour RN, Ohel G, Cohen M, Gonen R. Oral naproxen versus oral tramadol for analgesia after cesarean delivery. Int J Gynecol Obstet. 2011;113(2):144-7. doi: 10.1016/j.ijgo.2010.11.024

58. Fathi M, Zare MA, Bahmani HR, Zehtabchi S. Comparison of oral oxycodone and naproxen in soft tissue injury pain control: a double-blind randomized clinical trial. Am J Emerg Med. 2015 Sep;33(9):1205-8. doi: 10.1016/j.ajem.2015.05.021. Epub 2015 May 29.

59. Plapler PG, Scheinberg MA, Ecclissato CC, et al. Double-blind, randomized, doubledummy clinical trial comparing the efficacy of ketorolac trometamol and naproxen for acute low back pain. Drug Des Devel Ther. 2016;10: 1987-1993. doi: 10.2147/DDDT.S97756

60. Kivitz AJ, Moskowitz RW, Woods E, et al. Comparative Efficacy and Safety of Celecoxib and Naproxen in the Treatment of Osteoarthritis of the Hip. J Int Med Res. 2001 Nov-Dec;29(6):467-79.

61. Reginster J, Malmstrom K, Mehta A, et al. Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis. Ann Rheum Dis. 2007;66(7): 945-51. doi: 10.1136/ard.2006.059162

62. Singh G, Fort J, Goldstein J, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-1 study. Am J Med. 2006;119:255-66. doi: 10.1016/j.amjmed. 2005.09.054

63. Bombardier C, Laine L, Reicin A, et al. Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis. N Engl J Med. 2000;343(21): 1520-8. doi: 10.1056/NEJM200011233432103

64. Farkouh M, Kirshner H, Harrington R, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomized controlled trial. Lancet. 2004;364:675-84. doi: 10.1016/S0140-6736(04)16894-3

65. Nissen S, Yeomans N, Solomon D, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016 Nov 13. doi: 10.1056/NEJMoa1611593

66. Song G, Seo Y, Kim J, et al. Relative efficacy and tolerability of etoricoxib, celecoxib, and naproxen in the treatment of osteoarthritis: A Bayesian network meta-analysis of randomized controlled trials based on patient withdrawal. Z Rheumatol. 2016;75(5):508-16. doi: 10.1007/s00393-015-0023-9

67. Smith SR, Deshpande BR, Collins JE, et al. Comparative pain reduction of oral nonsteroidal anti-inflammatory drugs and opioids for knee osteoarthritis: Systematic analytic review. Osteoarthritis Cartilage. 2016;24(6): 962-72. doi: 10.1016/j.joca.2016.01.135

68. Van Hecken A, Schwartz J, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000;40(10):1109-20.

69. Hinz B, Cheremina O, Besz D, et al. Impact of naproxen sodium at over-the-counter doses on cyclooxygenase isoforms in human volunteers. Int J Clin Pharmacol Ther. 2008;46(4):180-6. doi: 10.5414/CPP46180

70. Schiff M, Hochberg M, Oldenhof J, Brune K. Platelet inhibitory effects of OTC doses of naproxen sodium compared with prescription dose naproxen sodium and low-dose aspirin. Curr Med Res Opin. 2009;25(10): 2471-7. doi: 10.1185/03007990903185706

71. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal antiinflammatory drugs: network meta-analysis. BMJ. 2011;342:7086. doi: 10.1136/bmj.c7086

72. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22:559-70. doi: 10.1002/pds.3437

73. Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: metaanalyses of individual participant data from randomised trials. Coxib and traditional NSAID Trialists' (CNT) Collaboration. Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.

74. Barcella CA, Lamberts M, McGettigan P, et al. Differences in cardiovascular safety with non-steroidal anti-inflammatory drug therapy – a nationwide study in patients with osteoarthritis. Basic Clin Pharmacol Toxicol. 2018 Nov 28. doi: 10.1111/bcpt.13182 [Epub ahead of print].

75. Asghar W, Jamali F. The effect of COX-2- selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17.

76. Antman E, Bennett J, Daugherty A, et al. Use of Nonsteroidal Antiinflammatory Drugs. An Update for Clinicians: A Scientific Statement From the American Heart Association. Circulation. 2007;115:1634-42. doi: 10.1161/CIRCULATIONAHA.106.181424

77. Burmester G, Lanas A, Biasucci L, et al. The appropriate use of non-steroidal antiinflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis. 2011;70(5):818-22. doi: 10.1136/ard.2010.128660

78. Non-steroidal anti-inflammatory drugs. Доступно по ссылке: https://www.nice.org.uk/advice/ktt13/resources/nonsteroidal-antiinflammatory-drugs-pdf-58757951055301

79. Karateev AE, Nasonov EL, Ivashkin VT, et al; Association of Rheumatologists of Russia, Russian Society for the Study of Pain, Russian Gastroenterology Association, Russian Scientific Medical Society of Therapists, Association of Traumatologists and Orthopedists of Russia, Russian Association of Palliative Medicine. Rational use of nonsteroidal anti-inflammatory drugs. Clinical guidelines. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2018;56(Suppl. 1):1–29 (In Russ.). doi: 10.14412/1995-4484-2018-1-29

80. Castellsague J, Riera-Guardia N, Calingaert B, et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12): 1127-46. doi: 10.1007/BF03261999

81. Bansal V, Dex T, Proskin H, Garreffa S. A look at the safety profile of over-the-counter naproxen sodium: a meta-analysis. J Clin Pharmacol. 2001 Feb;41(2):127-38. doi: 10.1177/00912700122009935

82. White WB, Kloner RA, Angiolillo DJ, Davidson MH. Cardiorenal Safety of OTC Analgesics. J Cardiovasc Pharmacol Ther. 2018 Mar;23(2):103-18. doi: 10.1177/1074248417751070


For citation:


Karateev A.E. A patient with osteoarthritis out of a doctor's field of vision: how should joint pain be controlled within the concept of responsible self-treatment? Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2S):52-61. (In Russ.) https://doi.org/10.14412/2074-2711-2019-2S-52-61

Views: 19


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2074-2711 (Print)
ISSN 2310-1342 (Online)